Start free

AIM ImmunoTech Inc. (AIM) insider trading

Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Nov 20, 2026.

Filings shown
15
Open-market buys
14
Open-market sells
0
Buys, 10b5-1 box not checked
14 of 14

Counts cover the 15 most recent Form 4 filings Tradune holds for AIM (filed Sep 15 – Nov 20, 2026). SEC EDGAR Form 4 filings for AIM last checked Nov 21, 2026, 09:00 UTC; the latest AIM filing Tradune holds was filed Nov 20, 2026. This is not guaranteed to be the complete record — see AIM's full Form 4 filing history on SEC EDGAR.

Open-market activity, last 90 days

Purchases (Form 4 code P) and sales (code S) on the 15 filings Tradune holds for AIM filed Sep 15 – Nov 20, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.

Open-market purchases and sales by insider
Insider Buys Sells Shares bought Shares sold Value
Thomas K. EquelsCEO & President 14 0 372,173 — +$58,826

Value = shares × the price reported on each Form 4 (+ purchases, − sales); every open-market line in this window disclosed a price.

Insider-activity score

56/ 100

Net insider purchases
1 distinct buyer14 buy · 0 sell txofficer buying

Summarises ~90 days of public SEC Form 4 activity — more distinct buyers, officer involvement and net buying score higher. A description of filing activity, not a rating or buy signal. How this score is computed →

Get alerted when insiders buy the stocks you own

Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.

Free for everyone right now · no card · nothing to buy

Start free

How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).

Insider Buying at AIM

Insiders reported 14 open-market purchases of AIM in the trailing 90 days, across 1 distinct buyer. The most recent purchase was reported by Thomas K. Equels (CEO & President) on Nov 19, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Recent Form 4 filings

Source: SEC EDGAR Form 4 · transaction codes explained

Thomas K. Equels CEO & President · filed Nov 20, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 50,000 $0.13 436,095 +13% Nov 19, 2026

† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.

“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.

Ted D. Kellner Director · filed Nov 20, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Disposition to issuer 250 $0.14 0 (indirect) −100% Nov 18, 2026
Disposition to issuer 14,574 $0.14 19,714 (indirect) −43% Nov 18, 2026
Disposition to issuer 2,702 $0.14 0 (indirect) −100% Nov 18, 2026
Thomas K. Equels CEO & President · filed Nov 18, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 20,000 $0.13 386,095 +5.5% Nov 18, 2026
Thomas K. Equels CEO & President · filed Nov 17, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 38,000 $0.14 366,095 +12% Nov 16, 2026
Thomas K. Equels CEO & President · filed Nov 13, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 35,000 $0.15 328,095 +12% Nov 11, 2026
Thomas K. Equels CEO & President · filed Nov 12, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 39,000 $0.14 293,095 +15% Nov 10, 2026
Thomas K. Equels CEO & President · filed Nov 10, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 31,298 $0.16 254,095 +14% Nov 9, 2026
Thomas K. Equels CEO & President · filed Nov 9, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 12,751 $0.16 222,797 +6.1% Nov 6, 2026
Thomas K. Equels CEO & President · filed Nov 6, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 20,299 $0.16 210,046 +11% Nov 6, 2026
Thomas K. Equels CEO & President · filed Oct 26, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 31,675 $0.16 189,747 +20% Oct 23, 2026
Thomas K. Equels CEO & President · filed Oct 23, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 31,250 $0.16 158,072 +25% Oct 22, 2026
Thomas K. Equels CEO & President · filed Sep 18, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 24,000 $0.21 126,822 +23% Sep 17, 2026
Thomas K. Equels CEO & President · filed Sep 17, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 11,000 $0.21 102,822 +12% Sep 16, 2026
Thomas K. Equels CEO & President · filed Sep 16, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 22,000 $0.22 91,822 +32% Sep 15, 2026
Thomas K. Equels CEO & President · filed Sep 15, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 5,900 $0.22 69,822 +9.2% Sep 14, 2026

Insider filings reported around the same time

Other companies whose most recent Form 4 was filed closest to AIM's (Nov 20, 2026).

Frequently asked about AIM insider activity

How many insiders bought AIM stock in the last 90 days?

1 distinct insider at AIM ImmunoTech Inc. reported 14 open-market purchases (Form 4 code P) of AIM shares in the trailing 90 days, the most recent filed by Thomas K. Equels (CEO & President) on Nov 19, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Who filed the most recent Form 4 for AIM?

The most recent Form 4 on this page was filed by Ted D. Kellner (Director) on Nov 20, 2026, reporting 3 transactions. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.

What was the largest open-market AIM insider purchase shown?

The largest open-market purchase among the filings shown was 50,000 AIM shares at $0.13 (about $6,550) by Thomas K. Equels (CEO & President) on Nov 19, 2026. Value is shares × the price reported on the Form 4; its Rule 10b5-1 box is not checked.

Do the recent AIM insider purchases have the Form 4 10b5-1 box checked?

No. All 14 AIM open-market purchases shown were reported with the Rule 10b5-1 box not checked. A blank box records what the filer disclosed; it does not prove that no plan exists. Latest: Thomas K. Equels (CEO & President) on Nov 19, 2026, 50,000 shares.

New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.

Get insider alerts for AIM — and your whole portfolio

Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy

This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.

Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.